

GHO Capital Investment in RoslinCT

Torreya advised RoslinCT on the transaction

London, United Kingdom, January 12, 2022

Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), a European specialist investor in global healthcare, announced the investment in RoslinCT, a leading Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies.

Established in 2006 in Edinburgh, Scotland, RoslinCT has worked to advance the field of regenerative medicine and today is at the forefront of high-quality cell therapy development and manufacturing. RoslinCT services an established, international customer base of blue-chip Pharma and Biotech companies, partnering from development phase through to late-stage clinical manufacturing. The business is set to benefit from exponential growth in the advanced therapy market which is forecast to grow at up to 50% annually.

With GHO's backing, RoslinCT will significantly increase its development and manufacturing capacity, supporting customer acquisition and product diversification. RoslinCT will benefit from GHO's sector expertise and international resources to accelerate growth, scaling the business to build on its best-in-class therapies and better service a growing international client base.

Torreya represented RoslinCT on this transaction. This highlights Torreya's strength in advising companies in the ATMP and CDMO sectors, in addition to our strong relationships in the healthcare sponsor community. Torreya has advised pharmaceutical services companies on almost \$1 billion in combined transaction value in the past 12 months.

ABOUT ROSLINCT:

For more information about RoslinCT, please see: www.roslinct.com

ABOUT GHO CAPITAL PARTNERS LLP:

For more information about GHO, please see: www.ghocapital.com

Deal Press Release

Torreya Contacts

ALAN SELBY

Managing Director | London Office

alan.selby@torreya.com | +44 (0) 207-451-4553 | [BIO](#)



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.